Phase 2 trial data showed average weight loss of up to 24.2% at 48 weeks, while the newer Phase 3 trial data showed 28.7% average weight loss at 68 weeks on the 12mg dose
The Global Anti-Obesity Drug Market is estimated to be valued at USD 30.58 Bn in 2026 and is expected to reach USD 98.63 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 18.2% from 2026 to 2033
Parker Parker is a member of the Public Finance, Tax Incentives and Credit Markets Group and has extensive experience in public, private, and public-private finance transactions and economic development matters across sectors and transaction roles
Thus, your DNA is protected and you live longer
By integrating advanced medical treatments with a holistic approach, we address not only weight management but also overall well-being, considering factors such as nutrition, physical activity, and emotional health